Introduction
In the 55 years since the first successful solid organ transplant, an increasing understanding of the adaptive alloimmune response has led to steady improvement in rejection-free survival of graft recipients. Nevertheless, the therapeutic potential of cardiac transplantation is limited by the development of chronic rejection in the form of cardiac allograft vasculopathy (CAV), which is present in 43% of recipients by the end of the eighth year after transplantation [1 ] .
The observation that peritransplant ischemic injury contributes significantly to accelerated arteriosclerosis in an alloantigen-independent fashion [2] has led to increasing interest in the effects of ischemia/reperfusion on the cardiac graft and, in particular, the response of the innate immune system to the injuries caused by the oxidative stress of ischemia/reperfusion. Ischemia/reperfusion injury activates the cellular (dendritic cells and innate lymphocytes) and humoral [natural immunoglobulin M (IgM) and complement] components of the innate immune system, which combine to trigger the innate immune response. The innate response in turn collaborates in the initiation and amplification of the adaptive alloimmune response that leads, ultimately, to rejection of the allograft.
Toll-like receptors
Among the best-understood actors in the innate immune system are the Toll-like receptors (TLRs), a family of transmembrane proteins expressed on epithelial cells, dendritic cells, macrophages, T-lymphocytes and Blymphocytes (Table 1 [3 , [4] [5] [6] 7 ] ). One of the most ancient components of the immune system, TLRs bind to conserved ligands on microbial pathogens such as lipopolysaccharide (LPS) on Gram-negative bacteria. TLRs are thought to be activated both by exogenous and by endogenous ligands [3 ] .
Release of endogenous ligands results from the ischemia/ reperfusion injury that follows global myocardial ischemia. Some of these ligands are the direct result of tissue injury. For example, the extracellular matrix polysaccharide hyaluronan [8] accumulates in the myocardial interstitium during allograft rejection and activates dendritic cells predominantly by binding to TLR4.
In addition to products of tissue injury, ischemia/reperfusion leads to the release of actively secreted messenger molecules that include heat-shock protein 70 and high-mobility group box 1 (HMGB1). Zou et al. [9 ] have demonstrated that ischemia/reperfusion leads to the release of heat-shock cognate protein 70 (HSC70) from the heart, and that this process in turn leads to the TLR4dependent inflammatory response. Isolated mouse hearts were subjected to 20 min of warm ischemia followed by 60 min of reperfusion. Prior to ischemia/reperfusion injury, HSC70 was detectable within the cytoplasm of cardiomyocytes but not in the coronary effluent; after ischemia/reperfusion, the protein was detectable in the coronary effluent and in the extracellular space. Expression of inflammatory cytokines tumor necrosis factor (TNF)a, interleukin (IL)-1 and IL-6 after ischemia/ reperfusion was reduced by antibody blockade of HSC70 and increased by treatment with recombinant HSC70 (rHSC70). In TLR4-deficient mice, there was no upregulation of inflammatory cytokines.
A role for HMGB1 in cardiac ischemia/reperfusion injury has also recently been established in mice [10] . Ligation of the left anterior descending artery led to increased HMGB1 expression within 30 min, with a peak 6 h after reperfusion. Ischemia/reperfusion injury was worsened by treatment with recombinant HMGB1 and ameliorated by inhibition of HMGB1.
Activation of TLR4 initiates an inflammatory cascade that contributestomyocardial dysfunctionafter ischemia/reperfusion injury. Cha et al. [11 ] demonstrated this effect by subjecting isolated mouse hearts to global ischemia. They found that, in comparison with wild-type animals, mice carrying mutations in TLR4 demonstrated significantly higher left ventricular diastolic pressure (LVDP) and dP/dt max 40, 50 and 60 min after reperfusion. Ischemia/ reperfusion was associated with a 6-8-fold increase in TNFa and a 6-15-fold increase in IL-1 in wild-type mice, but not in TLR4 mutants. There was a four-fold-increase in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) DNA-binding activity seen only in wild-type mice. Inactivating mutations of TNFa and IL-1 were similarly cardioprotective. In TLR4-deficient mice, an exogenous source of TNFa and IL-1 restored the deleterious effects of ischemia and reperfusion.
A similar effect was demonstrated in vivo in rats that had been subjected to 1 h of ischemia, followed by reperfusion [12] . In the ischemia/reperfusion group, TLR4 mRNA and protein levels increased with a peak at 1 h after reperfusion. There were significantly higher TNFa and IL-6 levels compared with a sham group. These data suggest an immediate harmful effect of TLR4-driven inflammation in the immediate posttransplant period.
Although these experiments were performed in models of myocardial infarction, a similar effect occurs after reperfusion of an ischemic, cold-preserved graft [13] . When syngeneic heart transplants are performed in TLR4-mutant mice after 2 h of cold ischemia, serum and graft levels of inflammatory cytokines [TNFa, IL-6, monocyte chemoattractant protein 1 (MCP-1) and IL-1b] are significantly lower than when the same transplants are performed in animals with intact TLR4. In the mutant mice, there is less translocation of myocardial NF-kB and reduced neutrophil infiltration. In addition to early myocardial dysfunction, TLR activation appears to promote subsequent development of CAV. Methe et al. [14] analyzed expression levels of TLR4 and its downstream targets (B7, IL-12 and TNFa) in the circulating monocytes of human cardiac transplant recipients. In the 13 of 38 patients that developed allograft endothelial dysfunction, expression of TLR4 and secretion of IL-12 and TNFa were significantly elevated compared with the remaining 25 patients. They observed a similar effect in mice receiving heterotopic heart transplants. Endothelial dysfunction is a highly sensitive and specific precursor to the development of CAV, suggesting that upregulation of TLR4 could be the first step in a chain of events leading to chronic rejection.
Activation of the innate immune system via TLRs can impair the development of tolerance [15] . In mice, transplanted organs that are protected from pathogenic stimuli (including the heart) are tolerated after blockade of the CD28-B7 costimulatory interaction using an anti-CD154 antibody. Those organs commonly exposed to antigens (lung, skin and bowel) are resistant to costimulatory blockade. When mice are treated with a TLR agonist, -C-phosphate-G-(CpG), at the time of an allogeneic heart transplant, administration of anti-CD154 does not lead to tolerance and allografts are rejected acutely [15] .
In anti-CD154-treated mice, forkhead box P3 (FoxP3) þ regulatory T cells (Tregs) accumulate in the graft, but this effect is not seen in TLR-stimulated mice.
Spontaneous tolerance to cardiac allografts is also impeded by TLR activation [7 ] . Although B6 and bm12 mice are major histocompatibility complex (MHC) class II disparate, B6 mice accept cardiac allografts from bm12 donors without immunosuppression, and the survival of skin grafts between these strains is prolonged more than 50 days by a short course of sirolimus and costimulatory blockade. When treated with the TLR agonist, CpG, long-term acceptance is prevented. [7 ] .
Treatment with CpG induces naive precursor T cells to differentiate into helper T cells (Th1) effector T cells and interferes with Treg suppression

Lymphocytes of the innate immune system
The understanding of the cellular components of the innate immune system is also evolving rapidly. Natural killer (NK) cells are lymphoid cells that were thought not to require sensitization to lyse foreign target cells ( Table 2 ). The 'missing self' hypothesis postulates that NK cells are activated by the absence of self-MHC molecules on target cells. Autoreactivity of NK cells is prevented by inhibitory receptors specific for self-derived MHC class I ligands. In addition, stimulatory receptors, most notably NK group 2, member D (NKG2D), recognize antigens on virally infected or tumor cells. When the balance of stimulatory and inhibitory signals received by the NK cell favors activation, the result is cell lysis by perforin and initiation of inflammation by cytokine release, principally interferon-gamma (IFNg). These cells were believed not to acquire immunologic memory or participate in the rejection of transplanted solid organs.
The conventional wisdom about NK cells has been challenged by several recent findings that could have profound implications for cardiac transplantation; NK cells now appear able to acquire a memory phenotype and to reject a transplanted organ.
Mouse NK cells carrying a receptor specific for cytomegalovirus (Ly49H) are induced to expand by viral infection. Sun et al. [16 ] demonstrated that, after a period of contraction, a portion of these expanded Ly49Hpositive cells lie dormant for 40-50 days and can mount a secondary expansion after a repeated stimulus. 'Memory' NK cells retain this property after adoptive transfer to a naive animal.
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In addition to acquiring a memory phenotype, NK cells are able to reject allogeneic skin grafts. Kroemer et al. [18 ] studied skin allograft rejection in Rag À/À mice, which lack T-lymphocytes and B-lymphocytes, and Rag À/À gc À/À mice, which additionally lack NK cells. Although skin grafts are heavily infiltrated by NK cells in the Rag À/À recipients, the grafts were not rejected in either group. When Rag À/À mice were treated with IL-15, the NK cell population expanded and rejected allogeneic (but not syngeneic) skin grafts. When IL-15 was withdrawn, the NK cell population returned to a resting state and did not reject a subsequent MHC disparate graft 30-40 days later.
Although blockade of the CD28-B7 costimulatory interaction with anti-CD154 leads to tolerance of cardiac allografts in mice, CD28-deficient mice remain able to reject cardiac allografts through a CD8-mediated process [19] . In these CD28 À/À mice, a subset of NK cells is recruited to allogeneic (but not syngeneic) grafts after transplantation. These NK cells are able, either directly via cytokine release or indirectly via promoting dendritic cell maturation, to promote antigen-specific CD8 þ Tlymphocyte proliferation leading to graft rejection [20] . Treatment of CD28 À/À mice with a neutralizing antibody against NKG2D, an activating receptor expressed by NK cells, prolonged the survival of cardiac allografts from 21.3 to 70.1 days [21] .
NK-dependent rejection has recently been demonstrated to be important in rejection of cardiac xenografts. In a mouse heart-to-rat xenotransplantation model [22] , rejection of xenogeneic tissue is associated with infiltration by macrophages and NK cells, with significant IFNg production and relatively little T-cell infiltration. Treatment with cyclosporine has no effect on survival, whereas depletion of NK cells with antiasialo-monosialotetrahexosylganglioside (GM-1) led to significant prolongation of graft survival.
Evidence for a critical role for NK cells in acute rejection in human patients is limited. A recent report [23] com-pared number of NK cells in peripheral blood and endomyocardial tissue in 20 patients with acute cellular rejection (ACR) (grade 3a) with 19 stable patients (grade 0). There was a significant depletion of NK cells in the blood of rejecting patients and an increase in CD16 þ NK cells in graft biopsy specimens, suggesting that NK cells home to the graft during rejection. A similar finding has been reported in recipients of lung transplants, although in this case, chronic rather than acute rejection was present [24 ] .
The importance of NK cells to the development of CAV was demonstrated in mice by transplanting hearts from parental donors to F1 hybrid recipients [25] . Solid organs transplanted in this fashion were accepted without immunosuppression; there was no host adaptive immune response, and the organs did not develop ACR. However, when hearts were removed at 56 days after transplant, 19 of 22 had developed advanced CAV. IFNg-deficient and T-cell-deficient recipients of parental-to-F1 hybrid transplants did not develop CAV.
The activation of NK cells may be facilitated by TLRmediated interactions with dendritic cells and macrophages. Stimulation of monocytes and macrophages with LPS leads to production of several ligands of NKG2D, including retinoic acid early inducible-1 (RAE-1) [26] and MHC class I-related chain A (MICA) [27] . In the presence of IL-2, TLR-activated monocytes were capable of stimulating NK cells to secrete IFNg. Hochweller et al. [28] were able to deplete dendritic cells efficiently by creating a transgenic mouse in which the diphtheria toxin receptor is expressed only in dendritic cells. They demonstrated that NK cells were activated by the TLR ligand CpG only in the presence of dendritic cells, and that production of IL-15 by dendritic cells is needed to maintain NK cell homeostasis .
Complement
Reperfusion exposes the graft endothelium to host complement proteins, potentially triggering a cascade leading to inflammation, coagulation and irreversible tissue damage. In a series of cardiac graft biopsy specimens 1-3 weeks after transplantation, deposition of C4d and C3d was histologically linked to peritransplant ischemic injury, and patients with complement deposition were more likely to demonstrate repeated episodes of rejection on later biopsies [29] . More recently, deposition of C4d has been strongly linked to the development of CAV in the first year after transplant [30] .
There is an increased expression of complement genes by graft-infiltrating leukocytes when ACR is present. Analysis of samples from human heart transplant recipient patients demonstrated higher transcript numbers of complement factor B, C3 and properdin and C3a receptor and C5a receptor as well as other genes potentially associated with rejection, including CD3, IFNg, perforin and granzyme B [31] .
Complement activity in the cardiac allograft appears to play a role in triggering alloreactive CD8 þ T-cells [32] . Complement activation is inhibited by decay-accelerating factor (DAF). When cardiac allografts from mice deficient in DAF are transplanted into wild-type hosts, graft rejection is accelerated in an antibody-independent fashion. In the absence of DAF, C3 production by graft cells leads to enhanced proliferation of alloreactive CD8 À cells.
Impaired complement activation may be protective against rejection in both animal models and human patients. When rats receiving heart transplants were treated with a blocking 'minibody' against C5 prior to transplantation, there was a reduction in cardiomyocyte apoptosis and necrosis and in levels of serum creatine phosphokinase and TNFa compared with untreated controls [33 ] . Mannose-binding lectin (MBL), a protein that is essential to the initiation of the lectin pathway of complement activation, is defective in 5-10% of patients. In a series of 90 heart transplant recipients, patients with MBL deficiency had fewer rejection episodes (6.3 AE 3.8%) than those with normal MBL (12.9 AE 11.6%) [34] .
Conclusion
Conventional immunosuppressive drugs, including antiproliferative agents and calcineurin inhibitors, target the adaptive immune system; the innate immune system is largely unaffected even by heavy immunosuppression. Improved understanding of innate immunity suggests several potential therapeutic targets, including blocking the response of TLRs to ischemia/reperfusion injury, depleting NK cells or blocking their activation and interfering with complement activation and deposition. Controlling the innate response may be the crucial missing piece in the puzzle of preventing CAV.
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